Back to Journals » Therapeutics and Clinical Risk Management » Volume 6

A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer

Authors English B, Baum C, Adelberg DE, Sissung TM, Kluetz P, Dahut W, Price DK, Figg W

Published 19 November 2010 Volume 2010:6 Pages 579—583


Review by Single anonymous peer review

Peer reviewer comments 3

Bevin C English1, Caitlin E Baum1, David E Adelberg3, Tristan M Sissung2, Paul G Kluetz3, William L Dahut3, Douglas K Price1, William D Figg1,2
1Molecular Pharmacology Section, 2Clinical Pharmacology Research Core, 3Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA

Abstract: A single nucleotide polymorphism (SNP) in CYP2C8 (rs1934951), was previously identified in a genome-wide association study as a risk factor for the development of osteonecrosis of the jaw (ONJ) in patients receiving bisphosphonates (BPs) for multiple myeloma. To determine if the same SNP is also associated with the development of ONJ in men receiving BPs for bone metastases from prostate cancer, we genotyped 100 men with castrate-resistant prostate cancer treated with bisphosphonates for bone metastases, 17 of whom developed ONJ. Important clinical characteristics, including type and duration of bisphosphonate therapy, were consistent among those who developed ONJ and those who did not. We found no significant correlation between the variant allele and the development of ONJ (OR = 0.63, 95% CI: 0.165–2.42, P > 0.47). This intronic SNP in CYP2C8 (rs1934951) does not seem to be a risk factor for the development of bisphosphonate-related ONJ in men with prostate cancer. It is important to note that this is only the second study to investigate the genetics associated with BP-related ONJ and the first to do so in men with prostate cancer. More studies are needed to identify genetic risk factors that may predict the development of this important clinical condition.

Keywords: bisphosphonates, ONJ, CYP2C8, polymorphism

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.